Your browser doesn't support javascript.
loading
IL-6 modulation for COVID-19: the right patients at the right time?
Ascierto, Paolo Antonio; Fu, Binqing; Wei, Haiming.
Afiliação
  • Ascierto PA; Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy paolo.ascierto@gmail.com.
  • Fu B; Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center; Department of Pathology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
  • Wei H; Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center; Department of Pathology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
J Immunother Cancer ; 9(4)2021 04.
Article em En | MEDLINE | ID: mdl-33837054
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Interleucina-6 / Anticorpos Monoclonais Humanizados / SARS-CoV-2 / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2021
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Interleucina-6 / Anticorpos Monoclonais Humanizados / SARS-CoV-2 / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2021